Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma
Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma
Rare inherited pathogenic germline variants observed in sporadic paediatric neuroblastoma cases
Mechanisms of acquired resistance to KRAS G12C inhibition in cancer
OncoAlert and ecancer weekly roundup for April 19 - 25, 2021
Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with resected stage IIIB-D/IV melanoma
High-quality neoantigens are immunoedited in long-term survivors of pancreatic cancer
Assessing comprehensive score for financial toxicity (COST) among radiation oncology patients in India
Highlights from AORTIC Cancer Genomics Conference 2021
Incorporating KRAS as a novel biomarker: Challenges and opportunities
Cancer Genomics in Africa today
Pre-operative staging with breast MRI
Imaging of lobular carcinoma